^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serotonin 1A-2A-2B-2C receptor antagonist

    1d
    Risperidone Treatment in Children and Adolescents: A Naturalistic Observational Study of Metabolic, Cardiac, and Clinical Outcomes. (PubMed, J Child Adolesc Psychopharmacol)
    Within 6 months of initiation, risperidone use in drug-naive pediatric patients was associated with increased weight and abdominal adiposity, early prolactin elevation, HDL reduction, and clinical improvement. Waist circumference showed a strong dose-dependent association and should be routinely monitored along with metabolic and endocrine parameters.
    Clinical data • Observational data • Journal
    |
    PRL (Prolactin)
    6d
    PSY-PGx: Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders (clinicaltrials.gov)
    P=N/A, N=1470, Recruiting, Maastricht University Medical Center | Not yet recruiting --> Recruiting | N=820 --> 1470
    Enrollment open • Enrollment change
    7d
    SLIM: Shortened LSD Intervention for Major Depressive Disorder (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Johns Hopkins University
    New P1 trial
    14d
    Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects (clinicaltrials.gov)
    P1, N=85, Recruiting, Medical University of Vienna
    New P1 trial
    19d
    CINEMA: Cerebellum-based Imaging Neural Markers for Antipsychotic Response (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Northwell Health
    New trial
    20d
    VCFS: The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (clinicaltrials.gov)
    P4, N=400, Recruiting, The Chaim Sheba Medical Center | Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2027
    Trial completion date • Trial primary completion date
    21d
    SUPPORT-SCZ: Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia (clinicaltrials.gov)
    P2, N=46, Completed, Hasanuddin University
    New P2 trial
    29d
    Chlorpromazine activates cGAS-STING signaling and reprograms the immune response in glioblastoma. (PubMed, Front Immunol)
    We demonstrate that CPZ, alone or in combination with temozolomide (TMZ), the current standard of care, activates the cGAS-STING signaling pathway, thus promoting anti-tumor immune responses. This study uncovers that CPZ exerts a previously unrecognized anti-cancer immunomodulatory activity, remodeling the immune microenvironment and enhancing the anti-tumor immune response. By overcoming TMZ resistance, CPZ not only exerts a direct anti-neoplastic effect, but also sensitizes GBM cells to standard therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    temozolomide
    1m
    Chlorpromazine inhibits EAG1 channels by altering the interdomain coupling. (PubMed, Biophys J)
    This further suggests that if chlorpromazine binding alters coupling between the PAS/CNBH domain ring, VSD and pore, as predicted by the network analysis, these alterations occur at potential more depolarized than the ones eliciting the Cole-Moore shift. Taken together, our study provides an insight into the allosteric pathways of EAG1 channel regulation by small molecule PAS domain binders.
    Journal
    |
    SPR (Sepiapterin Reductase)
    2ms
    Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole (clinicaltrials.gov)
    P4, N=31, Completed, Vanderbilt University Medical Center | Recruiting --> Completed | N=350 --> 31
    Trial completion • Enrollment change
    2ms
    Dexmedetomidine versus Chlorpromazine for Patients in ICU with Hyperactive Delirium: A Single-Center, Prospective, Double-Blind, Randomized Controlled Trial (ChiCTR2500114067)
    P=N/A, N=104, Not yet recruiting, Huashan Hospital Fudan University; Huashan Hospital Fudan University
    New trial
    4ms
    SEP-1: Subjective Experience Following Psilocybin (clinicaltrials.gov)
    P2, N=128, Not yet recruiting, University of Calgary | N=36 --> 128 | Trial completion date: Oct 2027 --> Jan 2028 | Trial primary completion date: Sep 2027 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date